Summit has presented new data from its Phase Ib modified diet trial of SMT C1100 in DMD and on its pre-clinical pipeline of 2nd generation compounds. Most importantly, the data confirms that a modified diet can positively impact the absorption of SMT C1100 and achieve potentially therapeutic levels. The results are highly supportive of the continued development of SMT C1100 and second-generation utrophin modulators in DMD, an ultimately fatal muscle wasting disease with no cure. We remain upbeat ....
